EA201891527A1 - Композиции и способы обнаружения и лечения рака пищевода - Google Patents

Композиции и способы обнаружения и лечения рака пищевода

Info

Publication number
EA201891527A1
EA201891527A1 EA201891527A EA201891527A EA201891527A1 EA 201891527 A1 EA201891527 A1 EA 201891527A1 EA 201891527 A EA201891527 A EA 201891527A EA 201891527 A EA201891527 A EA 201891527A EA 201891527 A1 EA201891527 A1 EA 201891527A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
cancer
ethesis
detection
Prior art date
Application number
EA201891527A
Other languages
English (en)
Other versions
EA037032B1 (ru
Inventor
Александр Приёр
Original Assignee
Прогастрин Э Кансер С.А Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прогастрин Э Кансер С.А Р.Л. filed Critical Прогастрин Э Кансер С.А Р.Л.
Publication of EA201891527A1 publication Critical patent/EA201891527A1/ru
Publication of EA037032B1 publication Critical patent/EA037032B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Abstract

Настоящее изобретение относится к способам диагностики рака пищевода in vitro и к композициям и способам для профилактики или лечения рака пищевода, где композиции содержат антитело, связывающееся с прогастрином, и способы включают применение антитела, связывающегося с прогастрином.
EA201891527A 2015-12-31 2017-01-02 Применение и способ для профилактики или лечения рака пищевода с использованием композиции, содержащей прогастрин-связывающее антитело EA037032B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307189 2015-12-31
EP16305139 2016-02-05
PCT/EP2017/050037 WO2017114976A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating esophageal cancer

Publications (2)

Publication Number Publication Date
EA201891527A1 true EA201891527A1 (ru) 2019-01-31
EA037032B1 EA037032B1 (ru) 2021-01-28

Family

ID=57821946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891527A EA037032B1 (ru) 2015-12-31 2017-01-02 Применение и способ для профилактики или лечения рака пищевода с использованием композиции, содержащей прогастрин-связывающее антитело

Country Status (14)

Country Link
US (2) US11789021B2 (ru)
EP (2) EP3848709A1 (ru)
JP (2) JP7018885B2 (ru)
KR (2) KR102430893B1 (ru)
CN (1) CN108700589A (ru)
AU (2) AU2017204686B2 (ru)
BR (1) BR112018013272A2 (ru)
CA (2) CA3193481A1 (ru)
EA (1) EA037032B1 (ru)
ES (1) ES2861587T3 (ru)
PL (1) PL3397967T3 (ru)
SG (1) SG11201805263TA (ru)
WO (1) WO2017114976A1 (ru)
ZA (1) ZA201804142B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
JP7338128B2 (ja) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル 癌診断における放射性標識プロガストリン
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
US20220356532A1 (en) * 2019-10-24 2022-11-10 The Johns Hopkins University Compositions and methods for detecting and treating esophageal cancer
JP7287532B2 (ja) * 2020-08-04 2023-06-06 王子ホールディングス株式会社 トイレットロール

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
JP2009529915A (ja) * 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110085986A1 (en) 2009-10-13 2011-04-14 Pomila Singh Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
JP5829672B2 (ja) 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ 結腸直腸及び胃腸癌の予防
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
CN105242045A (zh) * 2014-06-13 2016-01-13 拜奥希特公司 胃泌素-17作为具有增加的数种相关后发病风险的萎缩性胃炎的生物标志物的用途
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors

Also Published As

Publication number Publication date
AU2020202296A1 (en) 2020-04-23
PL3397967T3 (pl) 2021-06-28
US20190011447A1 (en) 2019-01-10
JP7018885B2 (ja) 2022-02-14
JP2019505785A (ja) 2019-02-28
ZA201804142B (en) 2019-11-27
CN108700589A (zh) 2018-10-23
WO2017114976A1 (en) 2017-07-06
EP3397967A1 (en) 2018-11-07
KR102197478B1 (ko) 2021-01-04
CA3193481A1 (en) 2017-07-06
EP3397967B1 (en) 2020-12-30
JP7363007B2 (ja) 2023-10-18
CA3009785A1 (en) 2017-07-06
JP2022064969A (ja) 2022-04-26
KR20210002363A (ko) 2021-01-07
KR102430893B1 (ko) 2022-08-09
AU2020202296B2 (en) 2022-06-02
AU2017204686B2 (en) 2020-04-30
US11789021B2 (en) 2023-10-17
BR112018013272A2 (pt) 2018-12-11
KR20180108586A (ko) 2018-10-04
US20240085423A1 (en) 2024-03-14
ES2861587T3 (es) 2021-10-06
SG11201805263TA (en) 2018-07-30
EA037032B1 (ru) 2021-01-28
EP3848709A1 (en) 2021-07-14
AU2017204686A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
EA202091540A1 (ru) Антитела к lilrb2
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
MX2018009700A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790413A1 (ru) Антитела против tigit
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201790173A1 (ru) Антитела, связывающие axl
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EA201592203A1 (ru) Способы лечения таупатии
EA201691541A1 (ru) Новые анти-baff антитела
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.